NLS Financial Statements From 2010 to 2024

NLSP Stock  USD 3.38  0.11  3.36%   
NLS Pharmaceutics financial statements provide useful quarterly and yearly information to potential NLS Pharmaceutics AG investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on NLS Pharmaceutics financial statements helps investors assess NLS Pharmaceutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting NLS Pharmaceutics' valuation are summarized below:
Market Capitalization
M
Earnings Share
(6.74)
There are currently one hundred twenty fundamental ratios for NLS Pharmaceutics that can be evaluated and compared over time across peers in the industry. Investors and active traders are advised to check NLS Pharmaceutics' last-minute fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction. As of 12/02/2024, Market Cap is likely to grow to about 1.1 B. Also, Enterprise Value is likely to grow to about 1.1 B
Check NLS Pharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NLS Pharmaceutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.8 K, Interest Expense of 137.9 K or Selling General Administrative of 6.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NLS financial statements analysis is a perfect complement when working with NLS Pharmaceutics Valuation or Volatility modules.
  
Check out the analysis of NLS Pharmaceutics Correlation against competitors.

NLS Pharmaceutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.3 M1.8 M2.7 M
Slightly volatile
Short and Long Term Debt Total1.4 M1.5 M5.8 M
Slightly volatile
Other Current LiabilitiesM1.7 M705 K
Slightly volatile
Total Current Liabilities4.5 M7.9 M2.6 M
Slightly volatile
Other Liabilities1.9 M3.2 M1.2 M
Slightly volatile
Accounts Payable2.7 M4.6 M1.6 M
Slightly volatile
Cash852.8 K897.7 K2.3 M
Pretty Stable
Non Current Assets Total22.4 K23.6 K107.9 K
Pretty Stable
Non Currrent Assets Other16 K16.9 K91.9 K
Pretty Stable
Other Assets0.860.932.3 K
Very volatile
Long Term Debt268 K282.1 K5.3 M
Slightly volatile
Cash And Short Term Investments852.8 K897.7 K2.3 M
Pretty Stable
Net Receivables10.1 K10.7 K63.5 K
Slightly volatile
Common Stock Total Equity151.8 K166.9 K137.3 K
Slightly volatile
Common Stock Shares Outstanding40.1 M38.2 M15.6 M
Slightly volatile
Liabilities And Stockholders Equity3.3 M1.8 M2.7 M
Slightly volatile
Non Current Liabilities Total3.4 M2.8 M6.4 M
Slightly volatile
Other Current Assets960.5 K914.7 K217.9 K
Slightly volatile
Other Stockholder Equity35.5 M61 M21.4 M
Slightly volatile
Total Liabilities6.6 M10.7 MM
Slightly volatile
Total Current Assets3.1 M1.8 M2.6 M
Pretty Stable
Common Stock770.1 K733.4 K264.5 K
Slightly volatile
Short and Long Term Debt1.3 M1.9 MM
Slightly volatile
Capital Stock397.9 K733.4 K242.4 K
Slightly volatile
Short Term Debt1.8 M1.9 M167.6 M
Pretty Stable
Deferred Long Term Liabilities663.9 K1.1 M479.7 K
Slightly volatile
Property Plant Equipment23.6 K26.6 K28.9 K
Slightly volatile

NLS Pharmaceutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense137.9 K145.2 K646.5 K
Slightly volatile
Selling General Administrative6.2 M5.9 M1.9 M
Slightly volatile
Other Operating Expenses8.6 M11.8 M6.9 M
Slightly volatile
Research Development4.5 M5.9 M4.2 M
Pretty Stable
Total Operating Expenses8.6 M11.8 M6.9 M
Slightly volatile
Selling And Marketing Expenses10.8 K11.4 K2.6 M
Very volatile
Cost Of Revenue12.1 K13.1 K10.5 K
Slightly volatile

NLS Pharmaceutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow9.4 M8.9 M2.2 M
Slightly volatile
Total Cash From Financing Activities1.6 M1.6 M6.4 M
Very volatile
End Period Cash Flow852.8 K897.7 K2.3 M
Pretty Stable
Depreciation9.8 K10.3 K4.8 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables1.6 M1.8 M1.4 M
Slightly volatile
Capex To Depreciation4.0E-44.0E-43.1491
Slightly volatile
Payables Turnover0.00480.00250.0054
Slightly volatile
Cash Per Share0.02230.02350.1594
Pretty Stable
Days Payables Outstanding76.6 K148.3 K70.5 K
Slightly volatile
Income Quality0.520.79560.7171
Pretty Stable
Current Ratio0.220.23021.6079
Slightly volatile
Graham Number1.221.28842.5575
Slightly volatile
Average Receivables29.8 K50.5 K31.4 K
Slightly volatile
Interest Debt Per Share0.04430.04660.5367
Slightly volatile
Debt To Assets0.971.025.7598
Very volatile
Days Of Payables Outstanding76.6 K148.3 K70.5 K
Slightly volatile
Ebt Per Ebit1.31.03091.1782
Very volatile
Quick Ratio0.220.23021.6106
Slightly volatile
Cash Ratio0.110.11331.5238
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9823
Slightly volatile
Debt Ratio0.971.025.7598
Very volatile

NLS Pharmaceutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.1 B897.9 M1.2 B
Slightly volatile
Enterprise Value1.1 B898.6 M1.2 B
Slightly volatile

NLS Fundamental Market Drivers

Cash And Short Term Investments897.7 K

NLS Upcoming Events

3rd of May 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About NLS Pharmaceutics Financial Statements

NLS Pharmaceutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although NLS Pharmaceutics investors may analyze each financial statement separately, they are all interrelated. The changes in NLS Pharmaceutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on NLS Pharmaceutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.9 B1.8 B
Cost Of Revenue13.1 K12.1 K

Pair Trading with NLS Pharmaceutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NLS Pharmaceutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NLS Pharmaceutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with NLS Stock

  0.62A Agilent Technologies Sell-off TrendPairCorr
  0.85ME 23Andme Holding Upward RallyPairCorr
  0.82VALN Valneva SE ADRPairCorr

Moving against NLS Stock

  0.75DRUG Bright Minds Biosciences TrendingPairCorr
  0.75SABSW SAB BiotherapeuticsPairCorr
  0.73VCYT VeracytePairCorr
  0.71VERA Vera TherapeuticsPairCorr
  0.53VCEL Vericel Corp OrdPairCorr
The ability to find closely correlated positions to NLS Pharmaceutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NLS Pharmaceutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NLS Pharmaceutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NLS Pharmaceutics AG to buy it.
The correlation of NLS Pharmaceutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NLS Pharmaceutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NLS Pharmaceutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NLS Pharmaceutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.